Search

RI 624

RI 624 is being developed by Rinat and is currently in Phase I clinical trials. … RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain.

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer.

Clenoliximab

Clenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

Bimakalim

Bimakalim is a small molecule drug. The usage of the INN stem '-kalim' in the name indicates that Bimakalim is a potassium channel activator, antihypertensive.

EVT 201

EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

Zuretinol acetate

Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).

MEM 1414

MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed. … MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.

Methyprylon

Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events. … Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia.

Methylisothiazolinone

Glyceryl laurate